Revive Therapeutics (TSE:RVV) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Revive Therapeutics is exploring the potential of Bucillamine, a drug with anti-inflammatory and antiviral properties, as a treatment for long COVID and as a countermeasure for nerve agent exposure. The company is in partnership with Defence R&D Canada to evaluate Bucillamine’s effectiveness against nerve agent-induced brain injury, with research completion expected by June 2024. Additionally, Revive Therapeutics is preparing a Phase 2 clinical study for long COVID, with a submission to the FDA anticipated by the end of March 2024.
For further insights into TSE:RVV stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue